Monte Rosa Therapeutics (GLUE) Competitors $5.67 -0.16 (-2.74%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$5.73 +0.06 (+1.08%) As of 03/25/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock GLUE vs. WVE, IMCR, ANIP, DYN, INDV, AMPH, ARDX, EVO, ETNB, and OCULShould you be buying Monte Rosa Therapeutics stock or one of its competitors? The main competitors of Monte Rosa Therapeutics include Wave Life Sciences (WVE), Immunocore (IMCR), ANI Pharmaceuticals (ANIP), Dyne Therapeutics (DYN), Indivior (INDV), Amphastar Pharmaceuticals (AMPH), Ardelyx (ARDX), Evotec (EVO), 89bio (ETNB), and Ocular Therapeutix (OCUL). These companies are all part of the "pharmaceutical products" industry. Monte Rosa Therapeutics vs. Wave Life Sciences Immunocore ANI Pharmaceuticals Dyne Therapeutics Indivior Amphastar Pharmaceuticals Ardelyx Evotec 89bio Ocular Therapeutix Monte Rosa Therapeutics (NASDAQ:GLUE) and Wave Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, community ranking, media sentiment, dividends, valuation, analyst recommendations, institutional ownership, risk and profitability. Which has preferable earnings & valuation, GLUE or WVE? Wave Life Sciences has higher revenue and earnings than Monte Rosa Therapeutics. Wave Life Sciences is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$14.98M23.26-$135.35M-$1.02-5.56Wave Life Sciences$108.30M13.38-$57.51M-$0.79-11.95 Do insiders & institutionals have more ownership in GLUE or WVE? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 89.7% of Wave Life Sciences shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 29.1% of Wave Life Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in GLUE or WVE? Wave Life Sciences received 349 more outperform votes than Monte Rosa Therapeutics when rated by MarketBeat users. Likewise, 67.72% of users gave Wave Life Sciences an outperform vote while only 48.48% of users gave Monte Rosa Therapeutics an outperform vote. CompanyUnderperformOutperformMonte Rosa TherapeuticsOutperform Votes1648.48% Underperform Votes1751.52% Wave Life SciencesOutperform Votes36567.72% Underperform Votes17432.28% Does the media favor GLUE or WVE? In the previous week, Monte Rosa Therapeutics had 16 more articles in the media than Wave Life Sciences. MarketBeat recorded 26 mentions for Monte Rosa Therapeutics and 10 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 1.31 beat Monte Rosa Therapeutics' score of 0.37 indicating that Wave Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 2 Very Positive mention(s) 6 Positive mention(s) 10 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Wave Life Sciences 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend GLUE or WVE? Monte Rosa Therapeutics presently has a consensus price target of $15.50, indicating a potential upside of 173.37%. Wave Life Sciences has a consensus price target of $22.60, indicating a potential upside of 139.41%. Given Monte Rosa Therapeutics' higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Wave Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75Wave Life Sciences 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Which has more risk and volatility, GLUE or WVE? Monte Rosa Therapeutics has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Wave Life Sciences has a beta of -1.04, suggesting that its share price is 204% less volatile than the S&P 500. Is GLUE or WVE more profitable? Monte Rosa Therapeutics has a net margin of 0.00% compared to Wave Life Sciences' net margin of -66.50%. Monte Rosa Therapeutics' return on equity of -62.68% beat Wave Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa TherapeuticsN/A -62.68% -38.83% Wave Life Sciences -66.50%-280.57%-52.90% SummaryWave Life Sciences beats Monte Rosa Therapeutics on 11 of the 19 factors compared between the two stocks. Remove Ads Get Monte Rosa Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLUE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GLUE vs. The Competition Export to ExcelMetricMonte Rosa TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$348.35M$3.03B$5.68B$8.30BDividend YieldN/A1.54%4.55%4.02%P/E Ratio-3.1029.9524.5519.25Price / Sales23.26447.85395.7294.10Price / CashN/A168.6838.1634.64Price / Book1.584.227.064.46Net Income-$135.35M-$71.72M$3.19B$247.07M7 Day Performance-15.37%-3.44%0.18%1.77%1 Month Performance-1.90%-9.94%5.53%-3.31%1 Year Performance-13.96%-23.03%14.21%5.26% Monte Rosa Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GLUEMonte Rosa Therapeutics2.3998 of 5 stars$5.67-2.7%$15.50+173.4%-33.0%$348.35M$14.98M-3.1090Earnings ReportAnalyst RevisionWVEWave Life Sciences4.5554 of 5 stars$10.17-0.5%$22.60+122.2%+63.3%$1.56B$108.30M-9.16240Positive NewsIMCRImmunocore2.0142 of 5 stars$30.04+4.3%$65.64+118.5%-53.1%$1.50B$310.20M-31.62320Positive NewsHigh Trading VolumeANIPANI Pharmaceuticals3.4555 of 5 stars$64.35+3.0%$79.75+23.9%-4.7%$1.40B$614.38M-117.00600DYNDyne Therapeutics3.2704 of 5 stars$12.31+2.2%$48.85+296.8%-56.3%$1.39BN/A-3.46100INDVIndivior3.4418 of 5 stars$9.99+3.2%$15.00+50.2%-53.8%$1.38B$1.19B-28.541,164Positive NewsAMPHAmphastar Pharmaceuticals4.0534 of 5 stars$27.69+3.9%$45.50+64.3%-34.9%$1.32B$731.97M9.231,620ARDXArdelyx4.363 of 5 stars$5.42-0.9%$10.95+102.0%-32.6%$1.29B$333.62M-33.8890EVOEvotec1.8047 of 5 stars$3.59+2.3%$5.93+65.3%-52.0%$1.27B$777.05M0.004,200ETNB89bio2.8387 of 5 stars$8.70+2.7%$27.56+216.7%-29.4%$1.27BN/A-2.9940Analyst ForecastOCULOcular Therapeutix3.3145 of 5 stars$7.94+2.8%$16.29+105.1%-20.0%$1.26B$63.72M-6.02230 Remove Ads Related Companies and Tools Related Companies WVE Alternatives IMCR Alternatives ANIP Alternatives DYN Alternatives INDV Alternatives AMPH Alternatives ARDX Alternatives EVO Alternatives ETNB Alternatives OCUL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GLUE) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold Hits $3,000… Here’s How You Can Get More for Under $20With gold surging to record highs, currently trading above $3,000 an ounce, and central banks aggressively sto...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monte Rosa Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monte Rosa Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
